Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)Dieter Koeberle, G. Bodoky, Karin Ribi et al.|Annals of Oncology|2016Cited by 140
Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).Dieter Koeberle, G. Bodoky, Jean‐François Dufour et al.|Journal of Clinical Oncology|2014Cited by 5